卡博康博:对先进细胞癌的第一线卡博桑提尼布+尼沃卢马布进行前性,第四期研究
Philippe Barthélémy1, Pascale Dutailly2, Bryan Qvick3
1Institut de Cancérologie Strasbourg Europe, 17 Rue Albert Calmette, Strasbourg, 67200, France.
卡博康博研究评估了卡博桑提尼布加尼沃卢马布在晚期细胞癌 (aRCC) 的现实有效性和耐受性. 这项研究提供了关于这种一线治疗组合患者结果的关键数据.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 药物经济学 药物经济学
背景情况:
- 根据CheckMate 9ER试验数据,第一线 (1L) 卡博桑提尼布加尼沃卢马布已被批准用于晚期细胞癌 (aRCC).
- 现实世界的数据对于补充治疗优化临床试验结果至关重要.
研究的目的:
- 评估1L卡博桑提尼布加尼沃卢马布在aRCC患者中的实际有效性和耐受性.
- 收集关于患者特征,治疗模式和结果在多样化的现实世界人口中的综合数据.
主要方法:
- 卡博科博是一项非干预性研究 (NCT05361434),在七个国家的70多个中心招募了311名患有清细胞aRCC的患者.
- 该研究将评估18个月的整体存活率作为主要终点.
- 二级终点包括无进展的生存率,客观反应率,安全性,治疗模式,后续疗法和生活质量.
主要成果:
- 该部分将在研究完成后填写.
- 将产生关于有效性和耐受性的现实世界的证据.
- 将收集有关治疗序列和患者结果的数据.
结论:
- 该CaboCombo研究旨在提供有价值的真实世界的证据,用于1L卡博桑提尼布加尼沃卢马布在aRCC.
- 结果将为临床实践和未来的研究方向提供信息,以治疗晚期癌.
- 这项研究将增强对广泛患者群体治疗结果的理解.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
